title: Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
abstract: BACKGROUND
  Paclitaxel (PTX) and doxorubicin (DOX) are widely used for the combined chemotherapy of solid tumors. However, free drug combination has lower antitumor efficiency. It is necessary to design a drug delivery system to carry both of them.
  
  
  OBJECTIVE
  This study aimed to engineer a nano-drug delivery system for co-encapsulating PTX and DOX. This system was expected to resolve the multidrug resistance caused by single drug, and the dual-drug-loaded nanostructured lipid carriers were also planned to specifically target the cancer cells without obvious influence on normal cells and tissues.
  
  
  METHODS
  In this paper, nanostructured lipid carriers for combination delivery of PTX and DOX were prepared by the melt-emulsification technique. In vitro cytotoxicity against NCL-H460 human non-small cell lung carcinoma (NSCLS) cell line was investigated, and in vivo anti-tumor of NLC was evaluated on mice models grafting NCL-H460 cells.
  
  
  RESULTS
  PTX-DOX NLC achieved the highest cytotoxic effect among all formulations in vitro, as compared to single drug delivery NLC. In vivo investigation on NSCLC animal models showed that co-delivery of PTX and DOX possessed high tumor-targeting capacity and strong anti-tumor activity.
  
  
  CONCLUSIONS
  The PTX-DOX NLC constructed in this research offers an effective strategy for targeted combinational lung cancer therapy.
authors.affiliation: a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and.
authors.forename: Yawei
authors.initials: Y
authors.lastname: Wang
authors.affiliation: b Department of Otorhinolaryngology Head and Neck Surgery , Provincial Hospital affiliated to Shandong University , Ji'nan , P.R. China.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Zhang
authors.affiliation: a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and.
authors.forename: Jing
authors.initials: J
authors.lastname: Hao
authors.affiliation: a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and.
authors.forename: Bei
authors.initials: B
authors.lastname: Li
authors.affiliation: a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.affiliation: a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and.
authors.forename: Wang
authors.initials: W
authors.lastname: Xiuwen
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D004359:Drug Therapy, Combination; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008175:Lung Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D051379:Mice; D049329:Nanostructures / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D004337:Drug Carriers; D008055:Lipids; D004317:Doxorubicin; D017239:Paclitaxel
keywords: Co-delivery; combination therapy; lung cancer; nanostructured lipid carriers; synergistic effect